UK: Revised Model Clinical Trials Agreement

Last Updated: 28 November 2006
Article by Sarah Hanson, Robert Amies and Shuna Mason

On 30 October 2006 the Department of Health, in partnership with the NHS, the Association of British Pharmaceuticals Industry (ABPI) and the BioIndustry Association (BIA), released a revised model Clinical Trials Agreement (mCTA). The revised mCTA is designed to speed up the contracting process and ensure early initialisation of research.

The mCTA was originally launched in 2003 by the DofH and the ABPI. It was intended for use in industry sponsored clinical trials in patients in NHS hospitals throughout the UK. The mCTA is not intended to cover collaborative research between industry and academia. It also specifically excludes research involving healthy volunteers.

To view the article in full, please see below:

Full Article

On 30 October 2006 the Department of Health, in partnership with the NHS, the Association of British Pharmaceuticals Industry (ABPI) and the BioIndustry Association (BIA), released a revised model Clinical Trials Agreement (mCTA). The revised mCTA is designed to speed up the contracting process and ensure early initialisation of research.

The mCTA was originally launched in 2003 by the DofH and the ABPI. It was intended for use in industry sponsored clinical trials in patients in NHS hospitals throughout the UK. The mCTA is not intended to cover collaborative research between industry and academia. It also specifically excludes research involving healthy volunteers.

The revised model contains modified provisions relating to trust liabilities, industry arrangements, intellectual property and dispute resolution and includes updates to reflect:

  1. Lessons learnt from the implementation of the older version;
  2. NHS organisational changes;
  3. Updates to legislation and research governance obligations; and
  4. Undertakings by industry to register trials and publish results.

The revised mCTA also includes a number of additional and revised definitions of commonly used terms within the agreement.

We have set out below some of the key changes made to the revised mCTA.


The revised mCTA makes a marked departure from its earlier stance in relation to the protocol outlining arrangements for trials across all countries and sites. Previously where any provisions of the mCTA conflicted with the protocol, the terms of the protocol would prevail. However under the new mCTA, the position has changed slightly. Now, where there is a conflict in relation to clauses dealing with liabilities/indemnities, confidentiality, data protection, freedom of information, publication or intellectual property, the terms of the mCTA will prevail.

The revised mCTA no longer makes any reference to foreign laws. This change means that sponsors must notify hospitals of any specific requirements related to performance of trials that arise under foreign laws.

Obligations of the Parties

The mCTA is designed to facilitate trial initiation, however delays often occur in getting the necessary regulatory approval for these trials. It has previously been noted that there are advantages to signing off mCTA agreements before such approval is obtained however these advantages need to be balanced with the danger of beginning the actual trials before authorisation is secured. Therefore under the new mCTA, the sponsor may not supply the Investigational Medicinal Product (IMP) to the trial site until it has all the necessary approvals, allowing the correct balance to be achieved.

Due to the removal of reference to foreign laws, the sponsor must, under the revised mCTA, specify to the investigator exactly what financial disclosures are necessary (i.e. where disclosures are required under the FDA rules).

In respect of the trial subjects, previously, issues have arisen in obtaining the required number. Under the new mCTA, hospitals are required to use their ‘best endeavours" to fulfil the recruitment target, however the new mCTA now provides some flexibility in the number of subjects to be obtained. If it does not appear that the required number is going to be met, then the revised mCTA permits the trial to be scaled back. Conversely, the trial may be expanded where participants are recruited more easily than anticipated.

In addition to the above, the revised mCTA outlines various provisions relating to access, research misconduct and regulatory authorities, including various reporting requirements. Most notably the revised agreement does not require the sponsor to report to the hospital on trial progress, nor does it require them or the hospital’s R&D director to review the site’s performance at the end of the trial.

Liabilities and Indemnities

The revised mCTA has imposed caps on a hospital’s liability to the sponsor. The caps are set at two levels depending on the nature of the breach. Liability for wilful and/or deliberate breaches of the agreement or breaches related to confidentiality, data protection and freedom of information, publication and/or intellectual property will be capped at twice the value of the contract. Liability for all other breaches committed by the hospital will be capped at contract value.

Freedom of Information

The revised mCTA includes provisions relating to the disclosure of information related to contract clinical trials. Newly negotiated obligations ensure that hospitals will take timely actions to inform the sponsor of any requests for information, consult with the sponsors about disclosing such information and inform them of any plans to disclose such information against the sponsor’s wishes.

Intellectual Property

The revised mCTA has included newly agreed IP clauses designed to protect the sponsor’s IP and give them ownership of any trial derived IP and know how, whilst allowing the site to exploit clinical procedures or related improvements attained during the course of the trial. The new provisions set out the following main principles:

  1. That each party is to retain ownership of any IP or know how owned or licensed before the agreement came into effect;
  2. Any IP or know how generated at the trial site that is related to the clinical trial, the IMP or the protocol (excluding any clinical procedures or related improvements) is the property of the sponsor;
  3. Such clinical procedures or related improvements at the trial site can be protected and exploited (depending on the inventor’s employer (i.e. hospital or university);
  4. The site of the trial has the right to use any know how obtained during the trials in it normal clinical work.

Dispute Resolution

As per the original mCTA, the parties are required, in the first instance, to attempt to solve any dispute through mediation. The revised mCTA has gone further by setting out a local procedure for mediation, increasing in formality where necessary. If the parties fail to mediate, the revised mCTA provides that either party may take the dispute to the courts in the jurisdiction in which the trial site is located.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 27/11/2006.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.